Prothena Biosciences

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Prothena Biosciences sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).

8 total trials 1 currently recruiting 3 completed early-phase tilt upper quartile by trial count

Prothena Biosciences: 8 sponsored US clinical trials, 1 recruiting.

Prothena Biosciences sponsors 8 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 3 completed. 2 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Primary Amyloidosis, with 1 trials.

Upper-quartile sponsor footprint

Prothena Biosciences sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Open and recent trials

8 total, page 1 of 1

RECRUITING Phase 1

Phase 1 Study of PRX019 in Healthy Adult Volunteers

NCT06699680
TERMINATED Phase 3

A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients With AL Amyloidosis

NCT04973137
TERMINATED Phase 2

Study in Subjects With Light Chain (AL) Amyloidosis

NCT03154047
COMPLETED Phase 2

The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis

NCT02632786
TERMINATED Phase 2

Open-label Extension Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis

NCT02613182
COMPLETED

Quality of Life (QOL) Registry for Patients With AL Amyloidosis

NCT02574676
TERMINATED Phase 3

The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis

NCT02312206
COMPLETED Phase 1

Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis

NCT01707264

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 3
Phase 3 2

Therapeutic Areas

Primary Amyloidosis 1
Healthy Participants Study 1

What is open in the Prothena Biosciences pipeline

1 recruiting of 8 indexed (13% open); 3 completed (38%).

Phase mix: 2 late (III/IV) vs 5 early (I/II) (early-phase heavy).

Top condition: Primary Amyloidosis (1 trial), 1 other listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Prothena Biosciences: open-pipeline peers nationwide

Peers matched on 8 registered trials and 13% open enrollment, not the therapeutic-area sidebar.

Prothena Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 681012141618 0%10%20%30%40% Total trials Recruiting share Prothena BiosciencesAB ScienceAbbott Point of CareAbeona TherapeuticsAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Addario Lung Cancer Medical InstituteAmerican UniversityAnnexonAnsun Biopharma
Prothena Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Prothena Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 8 trials (± recruiting share)

Sponsors near 13% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Prothena Biosciences page

8 registered trials is a research-attention snapshot, not an endorsement of Prothena Biosciences or any single study.

  • 1 of Prothena Biosciences's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Primary Amyloidosis is the condition Prothena Biosciences studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Primary Amyloidosis trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Prothena Biosciences pipeline card: 8 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.